SC0191 + bevacizumab

SC0191 + bevacizumab is an investigational combination therapy being evaluated in clinical trials for the treatment of advanced cancers, primarily metastatic colorectal cancer and advanced ovarian cancer. SC0191 is a novel agent (precise molecular class not specified in public sources) under development, while bevacizumab is a well-established monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis. The combination aims to leverage the anti-tumor properties of both agents—SC0191’s mechanism (not yet publicly detailed) and bevacizumab’s anti-angiogenic effect—to improve outcomes in patients with difficult-to-treat malignancies. Early-phase studies are assessing safety, pharmacokinetics, and preliminary efficacy of this regimen[1][2].